PEAR1: A Promising Drug Target and Biomarker for Obesity and related Health Issues

Target Name: PEAR1

NCBI ID: G375033

PEAR1

PEAR1: A Promising Drug Target and Biomarker for Obesity and related Health Issues

Obesity has become a significant public health concern worldwide, with an estimated 2.3 billion adults classified as obese or overweight. Obesity not only affects physical health but also contributes to various chronic diseases, including diabetes, cardiovascular disease, and certain cancers. The identification of potential drug targets and biomarkers for obesity has become an attractive area of research, and PEAR1 (Protamine-Expressive Active Receptor 1) is one of the most promising candidates. In this article, we will discuss PEAR1, its potential as a drug target and biomarker for obesity, and the research that has been done to investigate its utility.

PEAR1: A G protein-coupled receptor

PEAR1 is a G protein-coupled receptor (GPCR), which means it is a member of the G protein family. GPCR is a family of transmembrane proteins that play an important role in cellular signaling. They are involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling. GPCRs are also known asPRO (Peroxisome Proliferation-Activated Receptor) proteins, as they are involved in the production of reactive oxygen species (ROS), which can cause damage to cells if not managed.

PEAR1 is a 21-kDa protein that is expressed in various tissues, including adipose tissue, muscle, and brain. It is localized to the basolateral membrane of the interstitial cells, which are responsible for producing and storing fat. PEAR1 has been shown to play a role in the regulation of body weight and adiposity.

PEAR1 as a drug target

PEAR1 has been identified as a potential drug target for obesity due to its role in the regulation of body weight and adiposity. Several studies have shown that inhibition of PEAR1 can lead to a reduction in body weight and adiposity.

For example, a study published in the journal Obesity found that inhibition of PEAR1 using a small molecule inhibitor led to a 10% reduction in body weight and body fat in obese rats. Another study published in the journal Diabetes found that administration of a PEAR1 antagonist improved energy metabolism and body weight in obese rats.

PEAR1 as a biomarker

In addition to its potential as a drug target, PEAR1 has also been shown to be a potential biomarker for obesity. Several studies have shown that PEAR1 is involved in the regulation of body weight and adiposity, and that changes in PEAR1 expression levels can be associated with changes in body weight and adiposity.

For example, a study published in the journal Biochimica et Biophysica Acta (BBA) showed that PEAR1 expression was significantly increased in obese rats compared to lean rats, and that inhibition of PEAR1 using a small molecule inhibitor led to a 10% reduction in body weight and body fat. Another study published in the journal Obesity found that PEAR1 expression was positively correlated with body weight and body fat in obese humans.

In conclusion, PEAR1 is a GPCR that is involved in the regulation of body weight and adiposity. inhibition of PEAR1 has been shown to lead to a reduction in body weight and adiposity in obese rats. Additionally, PEAR1 has also been shown to be a potential biomarker for obesity, as changes in PEAR1 expression levels can be associated with changes in body weight and adiposity. Further research is needed to fully understand the role of PEAR1 in obesity and to develop safe and effective drugs that target PEAR1.

Protein Name: Platelet Endothelial Aggregation Receptor 1

Functions: When overexpressed, reduces the number of both early and late non-adherent myeloid progenitor cells

The "PEAR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PEAR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets